Polaryx Therapeutics Inc. Common Stock (PLYX)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I begin with durable earning power and a margin of safety. Polaryx has neither on the filed figures. It is a clinical-stage biotechnology company with no reported revenue in any period shown. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $1.4 million, or negative $0.03 per diluted share. In fiscal Q1 2026, the quarter ended 2026-03-31, it lost $2.5 million, or negative $0.05 per diluted share. For FY2025, it lost $9.0 million, or negative $0.20 per diluted share; for FY2024, it lost $30.4 million, or negative $0.89 per diluted share. The narrowing annual loss is a small positive, but the business still consumes cash: trailing free cash flow is negative $5.8 million, a negative 6.0% free cash flow yield on a $96.7 million market cap. Quality metrics are weak. FairStock calculates a Piotroski F-Score of 1/9, ROE of -96.56%, ROCE of -42.52%, and a FairStock Score of 13/100. The P/E of -13.86 is not meaningful because earnings are negative. At the 2026-10-13 close of $1.94, P/B is 8.82, so the market is paying a high multiple of book value for a business with no revenue. The Altman Z-Score of 55.30 is an outlier on the positive side, but I would not call the balance sheet proven from these figures alone. The 52-week range of $1.85 to $48.91 shows how speculative the shares have been. With only two years of filed results, the Lynch category is none because three years are needed. No commercial product, two employees, and a preclinical pipeline offer little competitive moat. This is a pipeline wager, not a Graham-style value investment.

In plain English: Polaryx Therapeutics is a small drug company with no products for sale yet, working on treatments for rare and childhood diseases. It loses money, spends cash, and has only a few employees, so the business looks weak. At $1.94, the stock is near its 52-week low, but with no sales or profits and a high price compared with its accounting value, it does not look cheap based on the current numbers; it looks speculative.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer